Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

CMA Commends Dept. Of Insurance Regulations That Will Protect Patients From Losing Their Health Insurance, California
The California Medical Association today praised the state Department of Insurance (DOI) for conducting a public hearing this week on its proposed regulations to prevent private insurers from unjustly canceling health coverage for patients after they get sick and file an expensive claim. The DOI released the proposed regulations last month.
generic viagra online
Three Organizations Form Alliance To Address Global Malnutrition
"Three internationally known organizations based in St. Louis - the Donald Danforth Plant Science Center, the Washington University School of Medicine and St. Louis Children"s Hospital" - have entered into a partnership, known as the Global Harvest Alliance (GHA), which aims to "create inexpensive, nutritionally complete food to help the world"s hungry and undernourished," the AP/Google.com reports. Alliance researchers will focus on several of the most successful approaches used to combat malnutrition and attempt to further enrich foods already used to fight it. "In addition, the alliance aims to help testing and distribution of crops genetically modified to boost nutritional content. They hope to provide the crops cheaply to farmers to produce more nutritious foods," writes the AP/Google.com (Taylor, 7/29).
News of the day
Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses In Metastatic Melanoma Patients
Plexxikon Inc. today announced preliminary data from a Phase 1 clinical study investigating PLX4032 (R7204). PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in most melanomas and about eight percent of all solid tumors. In patients whose cancer harbors this mutation and who were treated with therapeutic doses of PLX4032, tumor shrinkage and extended progression-free survival have been observed. Currently, two extension studies are being conducted in mutation-positive melanoma and colorectal cancer patients. Following the initial positive findings announced today, larger clinical trials to support a registration program for product approval are targeted to start later in 2009. Plexxikon and Roche are co-developing PLX4032 under their 2006 license and collaboration agreement.
Diagnostics

Yale Discovery May Open Door To Drug That Cuts Appetite And Boosts Energy

In a major advance in obesity and diabetes research, Yale School of Medicine scientists have found that reducing levels of a key enzyme in the brain decreased appetites and increased energy levels. Reductions in the levels of the enzyme prolylcarboxypeptidase (PRCP) led to weight loss and a decreased risk of type 2 diabetes in mice, according to research published in the August issue of The Journal of Clinical Investigation. The team found that PRCP is located in the hypothalamus and regulates levels of a peptide known for inhibiting food intake and stimulating energy expenditure- the alpha-melanocyte stimulating hormone (alpha-MSH). Researchers found that blocking the PRCP enzyme keeps the alpha-MSH peptides from being degraded, resulting in higher levels of alpha-MSH and decreased appetite. "Our research provides the first evidence that breaking down molecules in the brain that regulate metabolism is an important component of weight control," said senior author Sabrina Diano, associate professor in the Departments of Obstetrics, Gynecology and Reproductive Sciences, and Neurobiology. "Our findings provide a possible new target for the development of drugs to control metabolic disorders such as obesity and type 2 diabetes." Diano and her team conducted the study in congenic mice that were naturally lean and later in mice that had PRCP removed. Animals without the PRCP enzyme were leaner and ate less food. They also had higher levels of alpha-MSH in the hypothalamus compared to control animals. The mice were put on a diet of 45 percent fat-the equivalent of eating fast food everyday-and even with this high fat diet, they did not gain as much weight as control animals on a regular diet. Diano said the next step is to study how PRCP is regulated. Other authors on the study include Nicholas Wallingford, Bertrand Perroud, Qian Gao, Anna Coppola, Erika Gyengesi, Zhong-Wu-Liu, Xiao-Bing Gao, Adam Diament, Kari A. Haus, Zia Shariat-Madar, Fakhri Mahdi, Sharon L. Wardlaw, Alvin H. Schmaier and Craig H. Warden. Citation: The Journal of Clinical Investigation, Vol. 119, No. 8 (August 2009) Link: Sabrina Diano Yale University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009